Discovery of Clinical Candidate NT-0796, a Brain-Penetrant and Highly Potent NLRP3 Inflammasome Inhibitor for Neuroinflammatory DisordersDavid Harrison, Alan P. Watt, Jane Scanlon et al.|Journal of Medicinal Chemistry|2023Cited by 62
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome InhibitorsDavid Harrison, Alan P. Watt, Mark G. Bock et al.|ACS Medicinal Chemistry Letters|2022Cited by 23
Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances PotencyPamela J. Smolak, Christopher A. Gabel, MyTrang Nguyen et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1John R. Doedens, Christopher A. Gabel, Christine Diamond et al.|Biochemical Pharmacology|2024Cited by 5
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an <i>in vivo</i> tool compound for neuroinflammatory disordersDavid Harrison, Alan P. Watt, Peter Thornton et al.|RSC Medicinal Chemistry|2025Cited by 3